Scientists discover a NEW Ozempic that could burn twice as much fat as other weight-loss drugs

READ MORE: New weight loss drug revealed from California company  

A new weight loss drug could see patients lose double the amount of fat they'd shift on popular medications like Ozempic, early trial data has shown.

Obese patients taking the once-weekly injection lost roughly 19 percent of their body weight, on average, after five and a half months of the treatment.

In comparison, a number of trials have shown that semaglutide — the medication in Wegovy and Ozempic — results in around 10 percent reduction in body weight after six months.

Further, those with pre-diabetes on the new drug were all found to be in remission by the end of the trial.

The study data, unveiled by Swiss pharma giant Roche Thursday, show that the rate of side effects is similar to that of currently available injections.

Researchers found that those taking GLP-1 medications like Ozempic and Wegovy before an endoscopy had a 33 percent greater risk of developing aspiration pneumonia

The trial from Roche showed participants on the drug lost 18.8 percent of their body weight over 24 weeks on average

Roche's share price jumped four percent on the news of the new drug. Shown above over the last five days

Roche's share price jumped four percent on the news of the new drug. Shown above over the last five days

Side effects included mild to moderate gastrointestinal effects as well as nausea and vomiting.

The drug, called CT-388, was tested in a phase 1 trial, designed to check whether medications are safe for human use.

The study involved 31 obese adults with no underlying conditions including type 2 diabetes. A separate trial is planned to test the drug in diabetics.

Read More

What the latest Ozempic breakthrough means for you: It lowers the risk of heart attacks, and now there could be other diseases it helps fight. PAT HAGAN explains why doctors are so excited...

article image

At week 24, results showed that 45 percent of participants had lost more than 20 percent of their body weight.

Ozempic and Wegovy work by triggering the release of naturally occurring hormones that regulate blood sugar and suppress appetite.

Roche's drug acts similarly to Mounjaro and Zepbound, made by pharma firm Eli Lilly.

It contains the drug tirzepatide which, unlike semaglutide, acts on not one but two appetite-suppressing hormones.

CT-388 works by mimicking the hormone Glucagon-like peptide-1 (GLP-1), the same as in Ozempic.

But it also mimics the hormone Glucose-dependent insulinotropic polypeptide (GIP), which can help to slow the movement of food through the gut also ensuring someone feels fuller for longer.

Dr Levi Garraway, Roche's chief medical officer, said: 'We are very pleased to see the significant and clinically meaningful weight loss in people treated with CT-388.

'The results are highly encouraging for further development of CT-388 for both obesity and type 2 diabetes and underscore its potential to become a best-in-class therapy with durable weight loss and glucose control.'

The drug has a long way to go before it reaches the approval stage, with several further trials needed to prove efficacy.

A price for the medication also has not been revealed, but Ozempic retails at upwards of $900 per month.

The development comes as pharmaceutical companies race to cash in on the weight loss market boom, which is expected to surge to a value of $44billion by 2030, up from less than $100million in 2020.

More than nine million prescriptions were written for drugs including Ozempic, Wegovy and Mounjaro in the last three months of 2022, with companies racing to expand supply to meet the demand.

Roche's share prices climbed immediately after the announcement of the study results, jumping four percent.

Other companies have also seen their share prices surge after announcing new weight loss drugs, including Novo Nordisk which saw shares tick up more than eight percent in March after it reported a weight loss of 13 percent after 12 weeks in phase 1 trials of its new Amycretin pill.

Viking Therapeutics, based in California, saw its share value double after it reported phase two results for its own weight loss drug.

OTHER NEWS

19 minutes ago

At least 5 dead in North Texas after severe storms

19 minutes ago

Video: Megyn Kelly and Bill Maher get into awkward clash over her Trump support: 'You keep saying I'm nuts!'

19 minutes ago

Grayson Murray's family releases statement after 30-year-old golfer's death

19 minutes ago

Tottenham set to move for in-demand Brazilian striker in £60 million deal: report

19 minutes ago

Richard Sherman, Songwriter of Many Spoonfuls of Sugar, Dies at 95

23 minutes ago

National Park Superintendent sparks fury as she orders construction crew to stop flying the American flag because it 'distracts from the experience'

23 minutes ago

The sniper with one of the longest kills in Afghanistan has a message for Joe Biden

23 minutes ago

Navy Admiral warns Russian and Chinese nationals are trying to infiltrate US military bases

24 minutes ago

Alternative Solutions: Tapping into High Net Worth

24 minutes ago

Omar Farooq Premieres 'The Dark Side of Japan' at Sync Ithra

24 minutes ago

Brits divided on controversial mandatory National Service pledge

25 minutes ago

IRA Money Trail: D.C. drives clean energy boom

25 minutes ago

Marr scores 27 but Canada falls to Slovenia 3-2 in Volleyball Nations League

25 minutes ago

Division III school advances to College World Series days before it ceases operations

26 minutes ago

Cleveland Guardians at Los Angeles Angels odds, picks and predictions

26 minutes ago

Man Utd hold Thomas Frank and Mauricio Pochettino talks as Ten Hag sweats on review result

26 minutes ago

Nato countries plan 'completely new' drone wall along 1,340km Russian border

26 minutes ago

Hermione Norris open to Cold Feet reunion as women her age 'are snubbed from good roles'

26 minutes ago

10 unbelievable stats from Man Utd’s outstanding FA Cup final victory over Man City

26 minutes ago

Conference Board's Peterson Sees Consumer Spending Slowing

26 minutes ago

Southampton back in the Premier League after winning playoff final, the richest game in world soccer

26 minutes ago

‘Smoke and Mirrors’: Kgaogelo Monama, Sabelo Radebe announce pregnancy

26 minutes ago

Four Girls Stabbed At AMC Theater In Massachusetts, Suspect Arrested

26 minutes ago

Shane Watson hands out 'favourite' tag as KKR meet SRH in IPL 2024 final: 'Gives Sunrisers edge for sure...'

26 minutes ago

8 Dead in Texas, Oklahoma, and Arkansas After Freak Tornadoes Sweep Region

26 minutes ago

Southampton promoted to Premier League by beating Leeds in playoff final

26 minutes ago

Indianapolis 500 delayed as strong storm forces fans to evacuate Indianapolis Motor Speedway

26 minutes ago

Armenians throng center of the capital to demand the prime minister's resignation

26 minutes ago

Rishi Sunak’s National Service plan will ‘damage morale’ in the army, Tory minister warned

26 minutes ago

Jack Willis calls Antoine Dupont ‘best of all time’ after leading Toulouse to Champions Cup glory

34 minutes ago

Elon Musk plans to build largest-ever supercomputer

34 minutes ago

“That Paul Rudd makes me look like an Idiot manchild”: James Gunn’s Green Lantern Nathan Fillion Felt Ashamed After Belittling MCU’s Ant-Man

34 minutes ago

Top watering mistakes to avoid for healthier plants this summer

34 minutes ago

Penguins Legend Inducted into IIHF Hall of Fame

34 minutes ago

Behind the scenes of Taylor Swift's Eras Tour: $4.3 million on costumes, makeup & pure magic

35 minutes ago

Jack Draper crashes out of French Open to world number 176 Jesper De Jong

36 minutes ago

Bradley Cooper, 49, displays his cooking skills onstage while girlfriend Gigi Hadid, 29, shows her support at BottleRock Food and Music Festival

36 minutes ago

‘Furiosa’ Opening Action Muted With $59M Global Debut; Why Didn’t It Strong-Arm The Marketplace? – International Box Office

38 minutes ago

Vixens smash Fever's unbeaten Super Netball run

41 minutes ago

Woman Orders Coloring Book Online, Art Gets Increasingly Weird

Kênh khám phá trải nghiệm của giới trẻ, thế giới du lịch